Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Hepatitis CHIV
Interventions
DRUG

Ribavirin

"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)"

DRUG

Ribavirin plus Abacavir (ABC)

"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"

Trial Locations (1)

21287

Johns Hopkins Drug Development Unit, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

University of Colorado, Denver

OTHER

lead

Johns Hopkins University

OTHER

NCT01052701 - Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment | Biotech Hunter | Biotech Hunter